Tag Archives: biotech industry

Podcast with Joyce Cramer, Epilepsy Therapy Project

Biotech-Now’s Tracy Krughoff speaks with Joyce Cramer, president of the Epilepsy Therapy Project about the upcoming BIO Investor Forum and what this advocacy group looks for in terms of companies and projects. Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Targacept announces pricing of common stock offering

Targacept, Inc. (NASDAQ: TRGT) announced that the recently announced underwritten public offering of 2,200,000 shares of its common stock has been priced at a price to the public of $21.00 per share. As previously announced, Deutsche Bank Securities will act as sole manager for the offering and Targacept has granted Deutsche Bank Securities an option to purchase an additional 320,000 shares of common stock to cover over-allotments, if any. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical antifungal agent, in patients with tinea pedis (athlete’s foot). The study assessed the effectiveness of luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Long-term immune response for Vical’s TransVax™ vaccine in Phase 2 trial

Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Inovio reports clinical trial progress of cervical cancer vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) announced safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,